[go: up one dir, main page]

Dahlberg et al., 2025 - Google Patents

Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-Assembly

Dahlberg et al., 2025

View PDF
Document ID
15303866941110595297
Author
Dahlberg D
McKnight B
Kulkarni A
Rozumalski L
Rodriguez F
Wang Y
Wagner C
Publication year
Publication venue
bioRxiv

External Links

Snippet

T-cell engagers (TCEs) show promise in cancer immunotherapy but face challenges in solid tumors due to heterogeneity, antigen escape, and limited T-cell infiltration. To address this, we developed a modular platform using chemically self-assembled nanorings (CSANs). We …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments

Similar Documents

Publication Publication Date Title
Katsarou et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Cheng et al. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes
AU2023203601B2 (en) Ex vivo bite-activated T cells
Hegde et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
JP2023085479A (en) Synthetic immune receptors and methods of their use
JP6821688B2 (en) Chimeric antigen receptor and usage
Urbanska et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor
CN112840019B (en) Chimeric antigen receptor polypeptides combined with trans-metabolism molecules regulating the Krebs cycle and their therapeutic uses
JP2021512635A (en) Chimeric antigen receptor targeting the tumor microenvironment
EP3532490B1 (en) Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
JP2024178177A (en) Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
JP2020156488A (en) Compositions and Methods for Treating Cancer with Anti-mesocerin Immunotherapy
JP2020513829A (en) Compositions and methods for treating cancer by anti-CD33 immunotherapy
KR20200015717A (en) Utilization of CD39 and CD103 for Identification of Human Tumor Reactive T Cells for Cancer Treatment
JP2021510076A (en) Immune cells expressing chimeric antigen receptor
Chu et al. Human antibodies targeting ENPP1 as candidate therapeutics for cancers
Guo et al. The SpyCatcher-SpyTag interaction mediates tunable anti-tumor cytotoxicity of NK cells
Yu et al. Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma
Zhang et al. Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia
AU2023390820A1 (en) Chimeric antigen receptor
Kuo et al. Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
Domagala et al. Ammonia inhibits antitumor activity of NK cells by decreasing mature perforin
Dahlberg et al. Multivalent Tri-Functional T-cell Engagers by Chemically Induced Protein Self-Assembly
Wu et al. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma
Potez et al. Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells